Section Arrow
XBIO.NASDAQ
- Xenetic Biosciences
Quotes are at least 15-min delayed:2026/06/10 04:02 EDT
Pre Market
Last
 3.04
-0.043 (-1.39%)
Bid
3
Ask
4
High 3.04 
Low 3.04 
Volume 13 
Regular Hours (Closed)
Last
 3.083
-0.007 (-0.23%)
Day High 
3.09 
Prev. Close
3.09 
1-M High
3.495 
Volume 
5.95K 
Bid
3
Ask
4
Day Low
Open
3.08 
1-M Low
2.75 
Market Cap 
7.08M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.2 
20-SMA 3.11 
50-SMA 3.1 
52-W High 13.93 
52-W Low 1.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.19/-0.34
Enterprise Value
7.29M
Balance Sheet
Book Value Per Share
3.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.98M
Operating Revenue Per Share
0.94
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0289-0.021-42.08%-- 
Pre Market 0.0328 +0.0039 +13.49%
NUVLNuvalent123.25+34.76+39.28%-- 
Pre Market 123.25 0 0.00%
RXRXRecursion Pharmaceuticals3.22-0.1-3.01%-- 
Pre Market 3.22 0 0.00%
GERNGeron Corp1.12-0.01-0.88%-- 
Pre Market 1.15 +0.03 +2.68%
GOSSGossamer Bio0.16-0.0056-3.38%-- 
Pre Market 0.1617 +0.0017 +1.06%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.